ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
manuscript-chemrxiv-covid19.docx (6.8 MB)
0/0

Identification of Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach

preprint
revised on 09.04.2020 and posted on 10.04.2020 by Lovika Mittal, Anita Kumari, Mitul Srivastava, Mrityunjay Singh, Shailendra Asthana

In this work, computer-aided drug design method has been implemented to quickly identify promising drug repurposing candidates against COVID-19 main protease (Mpro) . The world is facing an epidemic and in absence of vaccine or any effective treatment, it has created a sense of urgency for novel drug discovery approaches. We have made an immediate effort by performing virtual screening of clinically approved drugs or molecules under clinical trials against COVID-19 Mpro to identify potential drug molecules. With given knowledge of this system, N3 and 13B compounds have shown inhibitory effect against COVID-19 Mpro. Both the compounds were considered as control to filter out the screened molecules. Overall, we have identified six potential compounds, Leupeptin Hemisulphate, Pepstatin A, Nelfinavir , Birinapant, Lypression and Octeotide which have shown the docking energy > -8.0 kcal/mol and MMGBSA > -68.0 kcal/mol. The binding pattern of these compounds suggests that they interacted with key hot-spot residues. Also, their pharmacokinetic annotations and therapeutic importance have indicated that they possess drug-like properties and could pave their way for in-vitro studies. The findings of this work will be significant for structure and pharmacophore-based designing.

Funding

The work has been supported by the facilities and support provided by THSTI.

History

Email Address of Submitting Author

sasthana@thsti.res.in

Institution

Translational Health Science and Technology Institute (THSTI)

Country

India

ORCID For Submitting Author

0000-0002-6143-7500

Declaration of Conflict of Interest

The authors declare that they do not have conflict of interest.

Exports